Effect of Invokana versus Januvia on A1C reduction, glucose levels, weight, and blood pressure
Invokana versus Januvia in reducing A1C
Invokana was compared to Januvia in a 52-week, randomized, double-blinded, active-controlled, phase 3 study of subjects (n=755) with type 2 diabetes treated with metformin plus a sulfonylurea. The first group of subjects was given 300 mg of Invokana daily, and the second group was given 100 mg of Januvia daily. When average baseline A1C was compared to average A1C after 52 weeks of treatment, Invokana resulted in an average A1C reduction of 1.03%, while the Januvia treated group had an average reduction in A1C of 0.66%. The difference was statistically significant. The proportion of subjects that reached an A1C of <7.0% was 47.6% for the Invokana group and 35.3% for the Januvia group. In addition, 22.5% of Invokana treated patients compared to 18.9% of subjects in the Januvia reached an A1C target of <6.5% at week 52.
Invokana versus Januvia in reducing fasting plasma glucose (FPG)
The average baseline FPG of patients treated with Invokana was (169.6 mg/dl) and the average baseline FPG was 163.8 mg/dl for patients treated with Januvia. At week 52, Invokana reduced FPG by 29.9 mg/dl while Januvia reduced FPG by 5.9 mg/dl.
Invokana versus Januvia in reducing body weight
The baseline body weight was 87.6 kg for subjects treated with Invokana and 89.6 kg for subjects treated with Januvia. At week 52, the body weight was measured and compared with baseline. It was found that Invokana was more effective in reducing body weight. Subjects treated with Invokana lost approximately 2.5% (-2.3 kg) while subjects treated with Januvia gained 0.3% (0.1 kg) in body weight.
Invokana versus Januvia in reducing systolic blood pressure (SBP)
The baseline SBP of subjects treated with Invokana was (131.2 mmHg) and the baseline SBP was (130.1 mmHg) for subjects treated with Januvia. Invokana was more effective in reducing SBP. The SBP in patients treated with Invokana decreased by 5.1 mmHg, while the SBP in patients treated with Januvia increased by 0.9 mmHg.